April 11, 2023 10:44 AM EDT
News Briefing

Bavar­i­an Nordic gath­ers pa­tients for PhI­II RSV tri­al; Adap­ti­m­mune hand­ed $37M+ as GSK part­ner­ship ends

Tyler Patchen

News Reporter

Dan­ish drug­mak­er Bavar­i­an Nordic grabbed head­lines last year for its pro­duc­tion of a vac­cine to treat the spread of mpox, and now it is turn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times